| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g | |||
| Other Sizes |
Purity: ≥98%
Geneticin G418 (G-418 disulfate) is a potent aminoglycoside antibiotic of the gentamicin B1 class, blocking polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells.
| Targets |
Aminoglycoside
|
|
|---|---|---|
| ln Vitro |
An aminoglycoside neomycin analogue called G418 sulfate inhibits protein synthesis and is widely used to select mammalian cell lines with neomycin resistance (NR). In eukaryotic vectors, the neomycin resistance (neo) gene is commonly employed as a dominant selectable gene. Asialoorosomucoid (AsOR) and G418 can be covalently bound to create a conjugate that is toxic and specific to hepatocytes[2].
MDA-MB231 cells were transfected with human GD3 synthase cDNA, and cells that stably overexpressed the enzyme were chosen using G-418 bulk selection[2]. Numerous pro- and eukaryotes have been demonstrated to be inhibited by the aminoglycoside antibiotic G418 at concentrations ranging from 1 to 300 micrograms/ml[4]. |
|
| ln Vivo |
|
|
| Cell Assay |
Acanthamoeba is a widely distributed opportunistic parasite which causes a vision-threatening keratitis and a life-threatening encephalitis. The cyst stage of this amoeba is especially resistant to currently used therapeutics and so alternative agents are urgently required. Growing evidence supports the existence of a programmed cell death system (PCD) in Acanthamoeba and while some features are shared by higher eukaryote cells, others differ. It is hoped that by understanding these differences we can exploit them as targets for novel drug intervention to activate PCD pathways in the amoebae but not the invaded human tissue. Here, we use the aminoglycoside G418 to activate PCD in Acanthamoeba. This drug caused a shape change in the treated amoebae. Cells rounded up and contracted, and after 6 h fragments of cells resembling the 'apoptotic bodies' of vertebrate cells were observed. G418 causes an increase in intracellular calcium from a resting level of 24 nM to 60 nM after 6 h of treatment. Mitochondrial function as assayed by the ΔΨm reporting dye JC-1 and CTC a redox dye becomes inhibited during treatment and we have found that cytochrome c is released from the mitochondria. Cells stained with Hoechst showed first an alteration in chromatin structure and then a vesiculation of the nucleus with G418 treatment, although we found no obvious breakdown in genomic DNA in the early stages of PCD [5].
|
|
| Animal Protocol |
Mouse RML and 22L prion inocula were obtained from RML- or 22L-infected CAD5 cells (34). The cells were grown to confluency, scraped in 1 ml PBS per 10 cm dish, and then homogenized using a Minilys bead homogenizer and CK14 homogenization tubes (Bertin). Benzonase (50 units/ml; EMD Millipore #70746-4) was added into the scraped culture, and then the culture was homogenized for three cycles of 30 s at maximum speed, with 5 min of incubation on ice between each cycle. Cell homogenates were then stored at −80 °C. Syrian hamster 263K prion inoculum was prepared in a similar way from 263K-infected CAD5-PrP−/− cells stably expressing HaPrP.[6]
|
|
| References |
[1]. An antibiotic selection marker for nematode transgenesis. Nat Methods. 2010;7(9):721-723. [5]. G418 induces programmed cell death in Acanthamoeba through the elevation of intracellular calcium and cytochrome c translocation. Parasitol Res. 2019 Feb;118(2):641-651.[6]. J Biol Chem. 2021 Sep;297(3):101073. doi: 10.1016/j.jbc.2021.101073. Epub 2021 Aug 12. |
|
| Additional Infomation |
Prions' ability to replicate in cultured cells has greatly facilitated prion research and the discovery of candidate therapies for prion diseases. The expression of different species of prion proteins in cells with low or no expression of endogenous prion proteins (PrP) has expanded the range of proliferating prion strains. In these systems, cells stably expressing the target PrP are typically obtained through co-expression of a selection marker and treatment with antibiotics. This article reports an unexpected finding: the aminoglycoside antibiotic G418 (genimycin) interferes with the ability of stably transfected cultured cells to be infected with prions. In G418-resistant N2a or CAD5 cell lines, the presence of G418 reduced the level of protease-resistant PrP produced after challenge with RML or 22L mouse prion strains. G418 also interfered with the infection of hamster PrP-expressing cells with 263K hamster prion strain. Interestingly, G418 had little or no effect on protease-resistant PrP levels in cells already infected with prions, suggesting that G418 selectively interferes with initial prion infection. Since G418 treatment had no significant effect on intracellular PrP levels or their localization, this suggests that G418 may specifically target prion assembly or be involved in the early stages of prion infection. [6]
|
| Molecular Formula |
C20H44N4O18S2
|
|---|---|
| Molecular Weight |
692.71
|
| Exact Mass |
692.209
|
| Elemental Analysis |
C, 34.68; H, 6.40; N, 8.09; O, 41.57; S, 9.26
|
| CAS # |
108321-42-2
|
| Related CAS # |
G-418;49863-47-0; 49863-47-0; 108321-42-2 (sulfate)
|
| PubChem CID |
206347
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
1012.1ºC at 760mmHg
|
| Flash Point |
565.9ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Source |
Micromonospora rhodorangea
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
44
|
| Complexity |
763
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].O([C@@]1([H])C([H])(C([H])(C([H])([C@]([H])(C([H])(C([H])([H])[H])O[H])O1)O[H])O[H])N([H])[H])C1([H])C([H])(C([H])([H])C([H])(C([H])(C1([H])O[H])O[C@@]1([H])C([H])(C([H])([C@](C([H])([H])[H])(C([H])([H])O1)O[H])N([H])C([H])([H])[H])O[H])N([H])[H])N([H])[H]
|
| InChi Key |
UHEPSJJJMTWUCP-DHDYTCSHSA-N
|
| InChi Code |
InChI=1S/C20H40N4O10.2H2O4S/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19;2*1-5(2,3)4/h6-19,24-30H,4-5,21-23H2,1-3H3;2*(H2,1,2,3,4)/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+;;/m1../s1
|
| Chemical Name |
(2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-2-((R)-1-hydroxyethyl)tetrahydro-2H-pyran-3,4-diol bis(sulfate)
|
| Synonyms |
Geneticin G418; Geneticin G-418; Geneticin G 418; Antibiotic G418;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Water : 100~125 mg/mL(~180.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (72.18 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline: 30mg/ml (43.31mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4436 mL | 7.2180 mL | 14.4361 mL | |
| 5 mM | 0.2887 mL | 1.4436 mL | 2.8872 mL | |
| 10 mM | 0.1444 mL | 0.7218 mL | 1.4436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
